EP1174153A2 - Gasemulsionen, die durch fluorierte Ether mit niedriegen Ostwaldkoeffizienten, stabilisiert sind. - Google Patents

Gasemulsionen, die durch fluorierte Ether mit niedriegen Ostwaldkoeffizienten, stabilisiert sind. Download PDF

Info

Publication number
EP1174153A2
EP1174153A2 EP01119824A EP01119824A EP1174153A2 EP 1174153 A2 EP1174153 A2 EP 1174153A2 EP 01119824 A EP01119824 A EP 01119824A EP 01119824 A EP01119824 A EP 01119824A EP 1174153 A2 EP1174153 A2 EP 1174153A2
Authority
EP
European Patent Office
Prior art keywords
ocf
gas
chf
och
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01119824A
Other languages
English (en)
French (fr)
Other versions
EP1174153B1 (de
EP1174153A3 (de
Inventor
Alexey Kabalnov
Ernest George Schutt
Jeffrey Greg Weers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imcor Pharmaceutical Co
Original Assignee
Alliance Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alliance Pharmaceutical Corp filed Critical Alliance Pharmaceutical Corp
Publication of EP1174153A2 publication Critical patent/EP1174153A2/de
Publication of EP1174153A3 publication Critical patent/EP1174153A3/de
Application granted granted Critical
Publication of EP1174153B1 publication Critical patent/EP1174153B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels

Definitions

  • the present invention includes a method for preparing stable, long-lived gas emulsions for ultrasound contrast enhancement and other uses, and to compositions of the gas emulsions so prepared. Additionally, the present invention includes precursors for preparing such emulsions.
  • Ultrasound technology provides an important and more economical alternative to imaging techniques which use ionizing radiation. While numerous conventional imaging technologies are available, e.g., magnetic resonance imaging (MRI), computerized tomography (CT), and positron emission tomography (PET), each of these techniques use extremely expensive equipment. Moreover, CT and PET utilize ionizing radiation. Unlike these techniques, ultrasound imaging equipment is relatively inexpensive. Moreover, ultrasound imaging does not use ionizing radiation.
  • MRI magnetic resonance imaging
  • CT computerized tomography
  • PET positron emission tomography
  • Ultrasound imaging makes use of differences in tissue density and composition that affect the reflection of sound waves by those tissues. Images are especially sharp where there are distinct variations in tissue density or compressibility, such as at tissue interfaces. Interfaces between solid tissues, the skeletal system, and various organs and/or tumors are readily imaged with ultrasound.
  • ultrasound performs suitably without use of contrast enhancement agents; however, for other applications, such as visualization of flowing blood, there have been ongoing efforts to develop such agents to provide contrast enhancement.
  • contrast enhancement agents One particularly significant application for such contrast agents is in the area of perfusion imaging.
  • Such ultrasound contrast agents could improve imaging of flowing blood in the heart muscle, kidneys, liver, and other tissues. This, in turn, would facilitate research, diagnosis, surgery, and therapy related to the imaged tissues.
  • a blood pool contrast agent would also allow imaging on the basis of blood content (e.g., tumors and inflamed tissues) and would aid in the visualization of the placenta and fetus by enhancing only the maternal circulation.
  • ultrasound contrast enhancement agents A variety of ultrasound contrast enhancement agents have been proposed. The most successful have generally consisted of dispersions of small bubbles of gas that can be injected intravenously. The bubbles are injected into the bloodstream of a living body to be imaged thereby providing an emulsion in the flowing blood that is of a different density and a much higher compressibility than the surrounding fluid tissue and blood. As a result, these bubbles can easily be imaged with ultrasound.
  • bubbles that are effective ultrasound scatterers in vivo have been difficult. Several explanations are apparent. First, such bubbles tend to shrink rapidly due to the diffusion of the trapped gas into the surrounding liquid. This is especially true of bubbles containing air or its component gases (such as nitrogen) which are highly soluble in water. It might be expected that bubble lifetime could be improved by simply increasing the size of the bubbles so more gas needs to escape before the bubbles disappear. This approach has proven unsatisfactory, however, because bubbles larger than about 10 ⁇ m in diameter are cleared from the bloodstream by the lungs, preventing their further circulation. Additionally, larger bubbles are not capable of circulating through smaller blood vessels and capillaries.
  • Microbubbles with satisfactory in vivo performance should also posses advantageous biological characteristics.
  • the compounds making up the gas inside the microbubbles should be biocompatible.
  • the microbubbles containing the gas phase will decay and the gas phase will be released into the blood either as a dissolved gas or as submicron droplets of the condensed liquid. Therefore, the gases will primarily be removed from the body through lung respiration or through a combination of respiration and other metabolic pathways in the reticuloendothelial system. Even when bubble persistence is sufficient to allow for several passes through the circulatory system of an animal or human, microbubble uptake by the reticuloendothelial phagocytic cells of the liver can limit the effectiveness of the contrast agent.
  • Adverse immune system reactions can also reduce the in vivo lifetimes of the bubble, and should be avoided.
  • "naked" microbubbles have been shown to produce adverse responses such as the activation of complement (See, for example, K.A. Shastri et al. (1991) Undersea Biomed. Res ., 18, 157).
  • these undesired responses may be reduced through the use of appropriate encapsulating agents.
  • the Epstein and Plesset formula leads to the formula for bubble lifetime ( ⁇ ) given by Quay in U.S. Patent 5,393,524: ⁇ ⁇ ⁇ / DC where ⁇ is the density of the entrapped gas, D is the diffusivity of the gas in the surrounding medium, and C is the solubility of the gas in the surrounding medium.
  • Quay forms bubbles using gases selected on the basis of being a gas at atmospheric pressure and body temperature (37°C) and having reduced water solubility, higher density, and reduced gas diffusivity in solution in comparison to air.
  • gases selected on the basis of being a gas at atmospheric pressure and body temperature (37°C) and having reduced water solubility, higher density, and reduced gas diffusivity in solution in comparison to air.
  • gases selected on the basis of low water solubility and high molecular weight. Specifically disclosed gases include SF 6 , and SeF 6 , as well as various perfluorinated hydrocarbons.
  • the Q value should be at least 30 to be a useful gas for ultrasound contrast enhancement.
  • a simple estimate using literature water solubility data (E. Wilhelm, R Battino, and R.J. Wilcock, Chemical Reviews, 1977, v. 77, p. 219) shows that the Q values of virtually all known gases (with the exception of hydrogen and helium) approach or exceed this value.
  • oxygen for example, has a Q of 20, and nitrogen has a Q of 35.
  • the Quay disclosure therefore, provides little guidance for the selection of effective microbubble gases.
  • the Quay Q coefficient criterion as well as Schneider's disclosure in EP0554213A1 fail to consider certain major causes of bubble shrinkage, namely, the effects of bubble surface tension, surfactants and gas osmotic effects, and the potential for filling gas condensation into a liquid. Namely, the partial pressure of the filling gas must be high enough to oppose the excess Laplace overpressure inside the bubbles. If the saturated vapor pressure is low the filling gas may condense into liquid and contrast ability will be lost. Accordingly, a need exists in the art for stabilized contrast enhancement agents that are biocompatible, easily prepared, and provide superior in vivo contrast enhancement in ultrasound imaging. A need also exists for microbubble precursors and methods to prepare and use such contrast enhancement agents.
  • the present invention utilizes low Ostwald coefficient fluoroether compounds to provide long lasting gas emulsions comprising microbubble preparations for ultrasound and magnetic resonance imaging contrast enhancement.
  • microbubble preparations are prepared using the compounds of the present invention, longer lasting images of the heart and other internal organs may be obtained than has been before possible.
  • gas emulsions comprising a previously unconsidered class of compounds which combine a reduced water solubility without a significantly reduced saturated vapor pressure (and thus surprisingly low Ostwald coefficients) are disclosed.
  • the high vapor pressure additionally helps to reduce the loss of contrast due to the filling gas condensation into liquid.
  • These compounds are the fluorinated mono- and polyethers.
  • a gas emulsion for ultrasound contrast enhancement comprising a plurality of gas bubbles in a liquid medium, with the gas comprising a fluoromono-or fluoropolyether, or a mixture thereof is disclosed.
  • the gas comprises a compound having an Ostwald coefficient of less than about 100 x 10 -6 at 37 degrees C, leading to especially long in vivo contrast enhancement. Vapor of perfluorodiethylether, perfluorodimethylether, perfluoromethylethylether,perfluoromonoglyme, perfluorodiglyme, C 4 F 10 O 3 , C 5 F 12 O 4 , C 6 F 14 O 5 have been found to be especially advantageous.
  • the gas bubbles of the present invention may be surrounded by a surfactant layer which preferably comprises a first and a second surfactant, the first surfactant consisting essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, with the second surfactant being more water soluble than the first surfactant.
  • a surfactant layer which preferably comprises a first and a second surfactant, the first surfactant consisting essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, with the second surfactant being more water soluble than the first surfactant.
  • the first surfactant comprises a phosphatidylcholine with one or more acyl chains, at least one chain comprising 12 to 18 carbon atoms
  • said second surfactant comprises a phosphatidylcholine with one or more acyl chains, at least one chain comprising 6 to 12 carbon atoms.
  • microbubble preparations of the present invention may be prepared using a number of different techniques.
  • microbubbles may be formed using the disclosed fluoroether compounds in conjunction with powders, protein microspheres, spray dried microspheres, void containing particles, particulates, liposomes, saturated sugar solutions, etc.
  • a liquid medium preferably water
  • gas emulsions may be formed.
  • the microbubbles are produced by spray drying a liquid formulation containing a biocompatible membrane-forming material to form a microsphere powder therefrom, combining the microspheres with the low Ostwald coefficient fluoroether compounds as disclosed herein, and mixing an aqueous phase with the powder.
  • the microsphere powder substantially dissolves in the aqueous phase to form microbubbles.
  • the microbubbles are coated with a monolayer of surfactant.
  • the present invention provides for methods of imaging, including harmonic ultrasonic imaging, using the disclosed gas emulsions.
  • Figure 1 is a graph of the in vivo pulsed Doppler signal intensity as a function of time from two fluoroether gas emulsions according to the present invention versus air.
  • Figures 2a, 2b and 2c are graphical representations of the decay of ultrasound signals over time following injection of gas emulsion contrast media into a rabbit. Each individual graphical representation is arranged in such a way that microbubble preparations comprising fluoroethers are compared to prior art microbubble preparations comprising fluorocarbon analogues.
  • Figures 3a, 3b, and 3c each show two ultrasound images of a pig heart before the injection of the bubble contrast media (Fig. 3a), 1 min (Fig. 3b) and 6 min (Fig. 3c) after injection.
  • the top image (other than the control images) is generated using a microbubble preparation comprising a perfluoropolyether, C 5 F 12 O 4
  • the bottom image was generated using a microbubble preparation comprising perfluorohexane, C 6 F 14 .
  • microbubbles are considered to be bubbles of gas in an aqueous medium having a diameter between about 0.5 and 300 ⁇ m, preferably having a diameter no more than about 200, 100, or 50 ⁇ m.
  • Microbubbles may or may not have a layer or coating at the gas/liquid interface. If present, the coating may be one or more molecules thick. Additionally, microbubbles may be trapped by a bimolecular layer (as in the case of unilamellar liposomes), or may be trapped by several layers of bilayers (multilamellar vesicles).
  • the microbubbles of the present invention may also be surrounded by more permanent shell-like structures such as denatured proteins.
  • the surfactant containing embodiments of the present invention are in essence gas emulsions, with the discontinuous phase of the emulsion being a gas, rather than a liquid. Consequently, the term "gas emulsion", as used herein, comprises a dispersion of a plurality of microbubbles of gas in an aqueous medium with or without a surfactant interface. That is, the gas emulsions of the present invention are simply microbubble preparations comprising a fluoroether.
  • Suitable microbubbles for vascular ultrasound contrast enhancement are therefore preferably about 1 - 10 ⁇ m in diameter, with 3-5 ⁇ m especially preferred.
  • the short lifetime of most microbubble preparations is caused in part by the increased gas pressure inside the bubble, which results from the surface tension forces acting on the bubble.
  • This elevated internal pressure increases as the diameter of the bubble is reduced.
  • the increased internal gas pressure forces the gas inside the bubble to dissolve, resulting in bubble collapse as the gas is forced into solution.
  • the Laplace pressure is inversely proportional to the bubble radius; thus, as the bubble shrinks, the Laplace pressure increases, increasing the rate of diffusion of gas out of the bubble and the rate of bubble shrinkage.
  • the stabilizing influence of proper gas combinations can be understood more readily through a discussion of certain hypothetical bubbles in aqueous solution.
  • the bubbles discussed may all be considered to be surrounded by a layer of surface tension reducing surfactant.
  • the effects of gas or gas combinations with differing solubilities, surfactant membrane layer permeabilities, and external concentrations will be considered.
  • the physical interactions of the primary modifier gas, secondary osmotic agent, and medium can be incorporated into a general theory of bubble behavior.
  • bubble lives can be determined theoretically as a function of certain physical characteristics of the secondary gas osmotic agent.
  • microbubble of radius r , containing two ideal gases: air (nitrogen) ( n a moles) and osmotic agent ( n F moles).
  • air nitrogen
  • n a moles osmotic agent
  • n F moles osmotic agent
  • the microbubble is in an infinite water medium, which contains no osmotic agent and is saturated with an infinite supply of air. Air is much more soluble in water and diffuses quickly out of the microbubble.
  • Treating the microbubble in a manner analogous to a semipermeable membrane we may consider that the chemical potential of air in the microbubble is the same as in the infinity, whereas the chemical potential of the fluorocarbon in the microbubble is higher than that in the infinity.
  • D is the osmotic agent-in-water diffusion coefficient
  • c F,subsurf is the equilibrium subsurface osmotic agent-in-water concentration.
  • the subsurface osmotic agent concentration in water to be in equilibrium with the fluorocarbon in the microbubble. Because the vapor is undersaturated, the subsurface concentration of the microbubble osmotic agent is lower than its saturated concentration, and is related to the internal osmotic agent vapor pressure as follows:
  • the combination RT C F,sat / P F,sat is dimensionless and has within it the ratio of the saturated osmotic agent vapor pressure to the corresponding equilibrium osmotic agent water solubility. This ratio is known as the Ostwald coefficient (often denoted "L").
  • the square of the microbubble radius decreases with time at a rate proportional to the Ostwald coefficient of the gas osmotic agent. Accordingly, gas osmotic agents with low Ostwald coefficients provide superior bubble longevity.
  • the Ostwald coefficient of the gas osmotic agent is preferably less than about 500 x 10 -6 , 100 x 10 -6 , or 50 x 10 -6 , most preferably less than about 40 x 10 -6 , 30 x 10 -6 , 20 x 10 -6 , 10 x 10 -6 , 5 x 10 -6 , or 1 x 10 -6 .
  • Table 1 shows the solubilities, vapor pressures, and Ostwald coefficients of several compounds, including certain biocompatible fluorocarbons.
  • Table 1 illustrates that perfluorobutane and perfluoropentane, which are gases at body temperature and atmospheric pressure, and which are contemplated as bubble gases by Quay and Schneider, have low Ostwald coefficients, and therefore also perform suitably as gas osmotic agents in conjunction with a primary modifier gas.
  • the ability to consider candidate compounds which are liquids at body temperature and atmospheric pressure allows the selection of certain optimal low Ostwald coefficient compounds that have not previously been considered in any way suitable for microbubble preparations.
  • Equation 7 is valid for bubbles containing gas combinations, where one of the gases is already present in the bloodstream, and where that gas (the “primary modifier gas”) can diffuse across the gas/liquid interface much faster than the other gas (the "gas osmotic agent”) in the combination. Only then is the partial pressure of the gas osmotic agent in the bubble equal to only the Laplace pressure rather than the total pressure inside the bubble. Because the Laplace pressure may be less than 1 atmosphere (at least for a large percentage of a bubble's lifetime) it is possible to use gas osmotic agents that are liquids at body temperature and atmospheric pressure. Such compounds would not form bubbles at all without the additional presence of the primary modifier gas.
  • the gas osmotic agent can be a liquid at body temperature, its saturated vapor pressure must be large enough so that the Laplace pressure does not immediately force the gas osmotic agent in the bubble to condense into a liquid.
  • the saturated vapor pressure of the gas osmotic agent is preferably larger than approximately 100 torr.
  • Perfluorinated hydrocarbons previously contemplated as microbubble filling gases have generally correlated water solubilities and saturated vapor pressures. That is, choosing a fluorocarbon with reduced water solubility also meant choosing a fluorocarbon with reduced saturated vapor pressure.
  • perfluorodiglyme CF 3 (OCF 2 CF 2 ) 2 OCF 3 , perfluoromonoglyme, CF 3 OCF 2 CF 2 CF 3 , perfluorodiethylether, C 2 F 5 OC 2 F 5 , perfluoroethylmethylether, CF 3 OC 2 F 5 , perfluorodimethylether, CF 3 OCF 3 , and perfluoropolyethers such as CF 3 OCF 2 OCF 3 , CF 3 (OCF 2 ) 2 OCF 3 , CF 3 (OCF 2 ) 3 OCF 3 , and CF 3 (OCF 2 ) 4 OCF 3 have been found to be especially suitable gas osmotic agents.
  • fluorinated ethers have the above described properties which make them especially suitable as gas osmotic agents for stabilizing gas emulsions.
  • the fluorinated ethers may be either gases or liquids at body temperature and atmospheric pressure.
  • Those fluorinated ethers which are gases at body temperature and atmospheric pressure are also useful as the sole gaseous component of a gas emulsion preparation.
  • a primary modifier gas though improving the efficacy of gas emulsions made with all gas osmotic agents, is not required if the fluorinated ether used is a gas at body temperature and atmospheric pressure.
  • useful fluorinated ether osmotic agents may be either completely or only partially fluorinated.
  • Some of the partially hydrogenated fluorinated ethers which are useful as gas osmotic agents according to the present invention are: CH 3 CH 2 OCF 2 CHF 2 , CH 3 CH 2 OCF 2 CF 3 , CHF 2 CH 2 OCF 2 CHF 2 , CF 3 CH 2 OCF 2 CH 2 F, CF 3 CH 2 OCH 2 CF 3 , CF 3 CH 2 OCF 2 CHF 2 , CHF 2 CH 2 OCF 2 CF 3 , CF 3 CH 2 OCF 2 CF 3 , CH 3 OCH 2 CF 2 CHF 2 , CH 3 OCH 2 CF 2 CF 3 , CH 3 OCF 2 CF 2 CHF 2 , CH 3 OCF 2 CHFCF 3 , CH 3 OCF 2 CF 2 CF 3 , CHF 2 OCH 2 CF 2 CHF 2 , CHF 2 OCH 2 CF 2 CF 3 , CF 3 OCH 2 CF 2 CHF 2 , CF 3 OCH 2 CF 2 CHF 2 , CH 3 O
  • microbubbles incorporating the gas may be formed in a variety of ways, both with and without a shell or surfactant interfacial layer, as is described in detail below.
  • Microbubble preparation methods include the formation of particulate microspheres through the ultrasonication of albumin or other protein as described in European Patent Applications 0,359,246 and 0,633,030 by Molecular Biosystems, Inc.; the use of tensides and viscosity increasing agents as described in U.S. Patent No. 4,446,442; lipid coated, non-liposomal, microbubbles as is described in U.S. Patent No. 4,684,479; liposomes having entrapped gases as is described in U.S. Patent Nos. 5,088,499 and 5,123,414; the use of amphipathic compounds as is described in U.S. Patent No.
  • the gas emulsions of the present invention include preparations of free gas microbubbles comprising fluoroethers. That is, in selected embodiments the gas emulsions of the present invention may be formed without the use of a surfactant as described in U.S. Patent Nos. 5,393,524 and 5,049,688 which are incorporated herein by reference.
  • the microbubble preparations may be prepared using sonication.
  • Sonication can be accomplished in a number of ways.
  • a vial containing a surfactant solution and gas in the headspace of the vial can be sonicated through a thin membrane.
  • the membrane is less than about 0.5 or 0.4 mm thick, and more preferably less than about 0.3 or even 0.2 mm thick, i.e., thinner than the wavelength of ultrasound in the material, in order to provide acceptable transmission and minimize membrane heating.
  • the membrane can be made of materials such as rubber, Teflon, mylar, urethane, aluminized film, or any other sonically transparent synthetic or natural polymer film or film forming material.
  • the sonication can be done by contacting or even depressing the membrane with an ultrasonic probe or with a focused ultrasound "beam.”
  • the ultrasonic probe can be disposable. In either event, the probe can be placed against or inserted through the membrane and into the liquid. Once the sonication is accomplished, the microbubble solution can be withdrawn from and vial and delivered to the patient.
  • Sonication can also be done within a syringe with a low power ultrasonically vibrated aspirating assembly on the syringe, similar to an inkjet printer. Also, a syringe or vial may be placed in and sonicated within a low power ultrasonic bath that focuses its energy at a point within the container.
  • bubbles can be formed with a mechanical high shear valve (or double syringe needle) and two syringes, or an aspirator assembly on a syringe. Even simple shaking may be used.
  • the shrinking bubble techniques described below are particularly suitable for mechanically formed bubbles, having lower energy input than sonicated bubbles. Such bubbles will typically have a diameter much larger than the ultimately desired biocompatible imaging agent, but can be made to shrink to an appropriate size in accordance with the present invention.
  • microbubbles can be formed through the use of a liquid osmotic agent emulsion supersaturated with a modifier gas at elevated pressure introduced into in a surfactant solution.
  • This production method works similarly to the opening of soda pop, where the gas foams upon release of pressure forming the bubbles.
  • bubbles can be formed similar to the foaming of shaving cream, with perfluorobutane, freon, or another like material that boils when pressure is released.
  • perfluorobutane, freon, or another like material that boils when pressure is released.
  • the emulsified liquid boils sufficiently low or that it contain numerous bubble nucleation sites so as to prevent superheating and supersaturation of the aqueous phase. This supersaturation will lead to the generation of a small number of large bubbles on a limited number of nucleation sites rather than the desired large number of small bubbles (one for each droplet).
  • a lyophilized cake of surfactant and bulking reagents produced with a fine pore or void-containing structure can be placed in a vial with a sterile solution and a head spaced with an osmotic gas mixture.
  • the solution can be frozen rapidly to produce a fine ice crystal structure and, therefore, upon lyophilization produces fine pores (voids where the ice crystals were removed).
  • any dissolvable or soluble void-forming structures or materials such as powdered and granulated sugars, may be used. It is not necessary that such structural materials define a plurality of voids prior to the addition of a liquid medium. Further, while it is preferable that the void-forming structures comprise a surfactant, this is not required for practicing the present invention. In this embodiment, where the void-forming material is not made from or does not contain surfactant, both surfactant and liquid are supplied into the container with the structures and the desired gas or gases. Upon reconstitution these voids trap the osmotic gas and, with the dissolution of the solid cake or powder, form microbubbles with the gas or gases in them.
  • dry void-containing particles or other structures that rapidly dissolve or hydrate, preferably in an aqueous solution, e.g., albumin, microfine sugar crystals, hollow spray dried sugar, salts, hollow surfactant spheres, dried porous polymer spheres, dried porous hyaluronic acid, or substituted hyaluronic acid spheres, or even commercially available dried lactose microspheres can be stabilized with a gas osmotic agent.
  • denatured protein microspheres are not particularly soluble, they are compatible with the present invention an may be used as void-containing structures in accordance with the teachings herein.
  • microbubble precursor compositions comprising:
  • structural material shall be held to mean any material defining a plurality of voids that promotes the formation of bubbles upon combination with a liquid medium.
  • Such structural materials which include both void-containing and void forming structures may be soluble or insoluble in an aqueous environment.
  • Exemplary structural materials that are compatible with the present invention include, but are not limited to, spray dried powders, powdered or granulated sugars, protein microspheres including denatured proteins microspheres, lyophilized cakes, lyophylized powders, salts, hollow surfactant spheres, dried porous polymer spheres and dried porous hyaluronic acid.
  • the structural material comprises a surfactant.
  • gas emulsion compositions incorporating low Ostwald coefficient gases are prepared by spray drying an aqueous dispersion which contains a hydrophilic monomer or polymer or combination thereof.
  • a bubble forming composition is formed by spray drying an aqueous dispersion of a hydrophilic moiety such as starch, preferably also including a surfactant, to form a structual material. More particlularly, form a powder of dry, hollow, approximately microspherical porous shells of approximately 1 to 10 ⁇ m in diameter, with shell thicknesses of approximately 0.2 ⁇ m.
  • the desired gas is made to permeate the structural material or dry microspheres by placing the microspheres into a vial, evacuating the air, and replacing it with the desired gas or gas mixture.
  • the hydrophilic moiety in the solution to be spray dried can, for example, be a carbohydrate, such as glucose, lactose, or starch.
  • Polymers such as PVA or PVP are also contemplated.
  • Various starches and derivatized starches have been found to be especially suitable.
  • Particularly preferred starches for use in formation of microbubbles include those with a molecular weight of greater than about 500,000 daltons or a dextrose equivalency (DE) value of less than about 12.
  • DE value is a quantitative measurement of the degree of starch polymer hydrolysis. It is a measure of reducing power compared to a dextrose standard of 100. The higher the DE value, the greater the extent of starch hydrolysis.
  • Such preferred starches include food grade vegetable starches of the type commercially available in the food industry, including those sold under the trademarks N-LOK and CAPSULE by National Starch and Chemical Co., (Bridgewater, NJ); derivatized starches, such as hydroxyethyl starch (available under the trademarks HETASTARCH and HESPAN from du Pont Pharmaceuticals, M-Hydroxyethylstarch from Ajinimoto, Tokyo, Japan).
  • starches with a molecular weight of 500,000 or above are preferred (Note that short chain starches spray dry well and may be used to produce microbubbles in accordance with the present invention.)
  • the hydrophilic monomer or polymer is present in this embodiment of the precursor solution at a range of about 0.1% to 10% w/v of solution, with about 1% to 5% w/v having been found to be especially suitable.
  • the aqueous dispersion also includes an optional surfactant or mixture of surfactants, provided at about 0.01% to 20% w/v of solution.
  • Surfactants may be selected from the group consisting of phospholipids, phosphocholines, lysophospholipids, nonionic surfactants, neutral or anionic surfactants, fluorinated surfactants, which can be neutral or anionic, and combinations of such emulsifying or foaming agents.
  • surfactants include block copolymers of polyoxypropylene and polyoxyethylene (an example of such class of compounds is Pluronic, such as Pluronic F-68), sugar esters, fatty alcohols, aliphatic amine oxides, hyaluronic acid aliphatic esters, hyaluronic acid aliphatic ester salts, dodecyl poly(ethyleneoxy)ethanol, nonylphenoxy poly(ethyleneoxy)ethanol, derivatized starches, hydroxy ethyl starch fatty acid esters, salts of fatty acids, commercial food vegetable starches, dextran fatty acid esters, sorbitol fatty acid esters, gelatin, serum albumins, and combinations thereof.
  • Pluronic such as Pluronic F-68
  • sugar esters include fatty alcohols, aliphatic amine oxides, hyaluronic acid aliphatic esters, hyaluronic acid aliphatic ester salts, dodecyl poly(ethyleneoxy)ethanol
  • polyoxyethylene fatty acids esters such as polyoxyethylene stearates, polyoxyethylene fatty alcohol ethers, polyoxyethylated sorbitan fatty acid esters, glycerol polyethylene glycol oxystearate, glycerol polyethylene glycol ricinoleate, ethoxylated soybean sterols, ethoxylated castor oils, and the hydrogenated derivatives thereof.
  • nonionic alkylglucosides such as Tweens® , Spans® and Brijs® are also within the scope of the present invention.
  • the Spans include sorbitan tetraoleate, sorbitan tetrastearate, sorbitan tristearate, sorbitan tripalmitate, sorbitan trioleate, and sorbitan distearate.
  • Tweens include polyoxyethylene sorbitan tristearate, polyoxyethylene sorbitan tripalmitate, polyoxyethylene sorbitan trioleate.
  • the Brij family is another useful category of materials, which includes polyoxyethylene 10 stearyl ether.
  • Anionic surfactants particularly fatty acids (or their salts) having 6 to 24 carbon atoms, may also be used.
  • a suitable anionic surfactant is oleic acid, or its salt, sodium oleate.
  • cationic surfactants and their salts such as dodecyltrimethylammonium chloride.
  • the solution contains a mixture of surfactants including a hydrophobic phospholipid as a first surfactant and at least one additional more hydrophilic second surfactant.
  • the hydrophobic phospholipid has at least one acyl chain with a total of at least about 10 carbon atoms (e.g. a didecanoyl phospholipid).
  • the phospholipid first surfactant will have acyl chains from about 10 or 14 to about 20 or 24 carbon atoms.
  • dipalmitoylphosphatidylcholine comprising two acyl chains, each comprising 16 carbon atoms
  • the acyl chain may be hydrogenated or fluorinated.
  • phospholipid head groups are also contemplated.
  • the phosphatidylserines, phosphatidylglycerols, or phosphatidylethanolamines will have properties suited to the present invention.
  • Combinations of such phospholipids can also comprise the "first surfactant," as can naturally derived phospholipid products such as egg or soy lecithin, or lung surfactants.
  • the phospholipid first surfactant may be supplemented with other highly water insoluble surfactants such as sucrose di-, tri-, and tetra-esters.
  • Cholesterol may also supplement the first surfactant, and has been found useful in promoting stability when provided in a range from about 0.01 to 0.5 w/w cholesterol to phospholipid.
  • the acyl chains of the phospholipid are saturated, although unsaturated acyl groups are also within the scope of the present invention.
  • the first surfactant is preferably provided in a range from about 0.005% to 20% w/v of the solution, most preferably in the range of 0.02% to 10% w/v.
  • a phospholipid mixture comprising a relatively hydrophobic long acyl chain phospholipid in combination with a shorter chain phospholipid which is more hydrophilic than the first phospholipid.
  • a first phospholipid having acyl chains with 12 or 14 carbon atoms may be provided with a second phospholipid as a co-surfactant having acyl chains with eight or ten carbon atoms.
  • phospholipid comprising 12 carbon atom acyl chains as either the first or second surfactants.
  • a phospholipid with 12 carbon atom acyl chains may comprise the first surfactant, and a sugar ester or Pluronic compound can comprise the second surfactant.
  • a phospholipid with 16 carbon atom acyl chains may comprise the first surfactant, and a phospholipid with 12 carbon atom acyl chains may comprise the second surfactant.
  • the spray dried product ultimately produced is a more effective bubble producer if an inflating agent, preferably a fluorocarbon such as Freon 113, is dispersed in the starch/surfactant solution described above.
  • the inflating agent can be any material that will turn to a gas during the spray drying process.
  • the inflating agent is dispersed throughout the surfactant solution, using, for instance, a commercially available microfluidizer at a pressure of about 5000 to 15,000 psi.
  • This process forms a conventional emulsion comprised of submicron droplets of water immiscible Freon (or other inflating agent) coated with a monomolecular layer of surfactant. Dispersion with this and other techniques are common and well known to those in the art.
  • an inflating agent in the solution to be spray-dried results in a greater ultrasound signal per gram of spray-dried powder by forming a greater number of hollow microspheres.
  • the inflating agent nucleates steam bubble formulation within the atomized droplets of the solution entering the spray dryer as these droplets mix with the hot air stream within the dryer.
  • Suitable inflating agents are those that supersaturate the solution within the atomized droplets with gas or vapor, at the elevated temperature of the drying droplets (approximately 100°C). Suitable agents include:
  • Inflating agents are added to the starch/surfactant solution-in quantities of about 0.5% to 10% v/v of the surfactant solution. Approximately 3% v/v inflating agent has been found to produce a spray dried powder which forms suitable microbubbles. The inflating agent is substantially evaporated during the spray drying process and thus is not present in the final spray-dried powder in more than trace quantities.
  • compositions within the aqueous phase.
  • agents may advantageously include conventional viscosity modifiers, buffers such as phosphate buffers or other conventional biocompatible buffers or pH adjusting agents such as acids or bases, osmotic agents (to provide isotonicity, hyperosmolarity, or hyposmolarity).
  • buffers such as phosphate buffers or other conventional biocompatible buffers or pH adjusting agents such as acids or bases, osmotic agents (to provide isotonicity, hyperosmolarity, or hyposmolarity).
  • Preferred solutions have a pH of about 7 and are isotonic.
  • These additional ingredients each typically comprise less than 5% w/v of solution.
  • suitable salts include sodium phosphate (both monobasic and dibasic), sodium chloride, calcium phosphate, and other physiologically-acceptable salts.
  • the various individual components of the microspheres preferably comprise the following proportions of the final spray dried product in % by weight: Hydrophilic structural material 1% to 100% Surfactant 0% to 90% Salts, buffer, etc. 0% to 90%
  • the composition has the following proportions in % by weight: Hydrophilic structural material 10% to 60% Surfactant 0.1% to 10% Salts, buffer, etc. 10% to 60%
  • the desired gas is made to permeate the dry microspheres by placing the microspheres into a vial, which is placed in a vacuum chamber to evacuate the air. The air is then replaced with the desired gas or gas mixture. The gas will then diffuse into the voids of the spheres. Diffusion can be aided by pressure or vacuum cycling.
  • the vial is then crimp sealed and preferably sterilized with gamma radiation or heat.
  • the first primary modifier gas (which may be air or any of its component gases such as nitrogen) and the second osmotic stabilizer gas (preferably having low Ostwald coefficient) are respectively present in a molar ratio of about 1:100, 1:75, 1:50, 1:30, 1:20, or 1:10 to about 1000:1, 500:1, 250:1, 100:1, 75:1 or 50:1.
  • the gas is nitrogen that has been saturated with perfluorodiglyme at 20 degrees C.
  • kits can be prepared for use in making the microbubble preparations of the present invention.
  • kits can include a container enclosing the gas or gases described above for forming the microbubbles, the liquid, and the surfactant.
  • the container can contain all of the sterile dry components, and the gas, in one chamber, with the sterile aqueous liquid in a second chamber of the same container.
  • the surfactant may be solubilized in the liquid prior to adding.
  • the present invention provides a method for preparing a gas emulsion comprising:
  • Suitable two-chamber vial containers are available, for example, under the trademarks WHEATON RS177FLW or S-1702FL from Wheaton Glass Co., (Millville, NJ).
  • Another example is provided by the B-D HYPAK Liquid/Dry 5+5 ml Dual Chamber prefilled syringe system (Becton Dickinson, Franklin Lakes, NJ; described in U. S. Patent 4,613,326).
  • the advantages of this system include:
  • Example VIII The use of the two chamber syringe to form microbubbles is described in Example VIII.
  • aqueous phase can be interposed between the water-insoluble osmotic gas and the environment, to increase shelf life of the product.
  • a material necessary for forming the microbubbles is not already present in the container, it can be packaged with the other components of the kit, preferably in a form or container adapted to facilitate ready combination with the other components of the kit.
  • microbubbles of the present invention include perfusion imaging of the heart, the myocardial tissue, and determination of perfusion characteristics of the heart and its tissues during stress or exercise tests, or perfusion defects or changes due to myocardial infarction.
  • myocardial tissue can be viewed after oral or venous administration of drugs designed to increase the blood flow to a tissue.
  • visualization of changes in myocardial tissue due to or during various interventions such as coronary tissue vein grafting, coronary angioplasty, or use of thrombolytic agents (TPA or streptokinase) can also be enhanced.
  • TPA or streptokinase thrombolytic agents
  • these contrast agents can be administered conveniently via a peripheral vein to enhance the visualization of the entire circulatory system, they will also aid in the diagnosis of general vascular pathologies and in the ability to monitor the viability of placental tissue ultrasonically.
  • the present invention provides for a method for harmonic ultrasound imaging using the disclosed gas emulsions as contrast agents.
  • the bubbles of the present invention are especially useful in harmonic imaging methods such as those described in co-pending United States patent application 08/314,074.
  • the present invention advantageously provides for the use of microbubbles capable of generating harmonics at medically useful ultrasound exciting amplitudes.
  • the present invention have applications beyond ultrasound imaging. Indeed, the invention is sufficiently broad to encompass the use of phospholipid-containing gas emulsions in any system, including nonbiological applications.
  • microbubble formulations of the present invention can be included in the microbubble formulations of the present invention.
  • osmotic agents stabilizers, chelators, buffers, viscosity modulators, air solubility modifiers, salts, and sugars can be added to modify the microbubble suspensions for maximum life and contrast enhancement effectiveness.
  • sterility, isotonicity, and biocompatibility may govern the use of such conventional additives to injectable compositions.
  • the use of such agents will be understood to those of ordinary skill in the art and the specific quantities, ratios, and types of agents can be determined empirically without undue experimentation.
  • any of the microbubble preparations of the present invention may be administered to a vertebrate, such as a bird or a mammal, as a contrast agent for ultrasonically imaging portions of the vertebrate.
  • the vertebrate is a human, and the portion that is imaged is the vasculature of the vertebrate.
  • a small quantity of microbubbles e.g., 0.1 ml/Kg [2 mg/Kg spray-dried powder] based on the body weight of the vertebrate
  • Other quantities of microbubbles such as from about 0.005 ml/Kg to about 1.0 ml/Kg, can also be used. Imaging of the heart, arteries, veins, and organs rich in blood, such as liver and kidneys can be ultrasonically imaged with this technique.
  • Microbubbles with an average number weighted size of 5 microns were prepared by sonication of an isotonic aqueous phase containing 2% Pluronic F-68 and 1% sucrose stearate as surfactants, air as a modifier gas and perfluorohexane as the gas osmotic agent.
  • the vial was turned horizontally, and a 1/8" (3 mm) sonication probe attached to a 50 watt sonicator model VC50, available from Sonics & Materials was pressed gently against the septum. In this position, the septum separates the probe from the solution. Power was then applied to the probe and the solution was sonicated for 15 seconds, forming a white solution of finely divided microbubbles, having an average number weighted size of 5 microns as measured by Horiba LA-700 laser light scattering particle analyzer.
  • the dry, hollow spherical product had a diameter between about 1 ⁇ M and about 15 ⁇ M and was collected at the cyclone separator as is standard for this dryer.
  • Aliquots of powder 250 mg were weighed into 10 ml tubing vials, evacuated and sparged with perfluorohexane-saturated nitrogen at 13°C and sealed. The nitrogen was saturated with perfluorohexane by passing it through three perfluorohexane filled gas washing bottles immersed in a 13°C water bath.
  • Solution 2 was added to high shear mixer and cooled in an ice bath.
  • This suspension was emulsified using a Microfluidizer (Microfluidics Corporation, Newton, MA; model M-110F) at 10,000 psi, 5°C for 5 passes.
  • the resulting emulsion was added to solution 1.
  • This mixture was then spray dried in a Niro Atomizer Portable Spray Dryer equipped with a two fluid atomizer (Niro Atomizer, Copenhagen, Denmark) employing the following settings: hot air flow rate 31 CFM inlet air temp. 370 °C outlet air temp. 120 °C atomizer air flow 290 liters/min emulsion feed rate 1.5 liter/hr
  • the dry, hollow spherical product had a diameter between about 1 ⁇ M and about 15 ⁇ M and was collected at the cyclone separator as is standard for this dryer.
  • Aliquots of powder 200 mg were weighed into 10 ml tubing vials, sparged with perfluorodiglyme-saturated nitrogen at 20°C and sealed. The nitrogen was saturated with perfluorodiglyme by passing it through three perfluorodiglyme filled gas washing bottles immersed in a 20°C water bath. The amount of perfluorodiglyme vapor per vial was 12-14 mg.
  • the vials were reconstituted with 5 ml water for injection after inserting an 18-gauge needle as a vent to relieve pressure as the water was injected, forming approximately 6 x 10 8 bubbles per ml which were stable in vitro for several days.
  • One ml of the resulting microbubble suspension was injected intravenously into an approximately 3 kg rabbit instrumented to monitor the Doppler ultrasound signal of its carotid artery.
  • a 10 MHz flow cuff (Triton Technology Inc., San Diego, CA; model ES-10-20) connected to a System 6 Doppler flow module (Triton Technology Inc.) fed the RF Doppler signal to a LeCroy 9410 oscilloscope (LeCroy, Chestnut Ridge, NY).
  • the root mean square (RMS) voltage of the signal computed by the oscilloscope was transferred to a computer and the resultant curve fitted to obtain peak echogenic signal intensity and half-life of the microbubbles in blood. Signals before contrast were less than 0.1 volts RMS.
  • signal intensity was 1.1 V rms, with a decay constant of approximately .00859 s -1
  • Solution 2 was added to high shear mixer and cooled in an ice bath.
  • This suspension was emulsified using a Microfluidizer (Microfluidics Corporation, Newton, MA; model M-110F) at 10,000 psi, 5°C for 5 passes.
  • the resulting emulsion was added to solution 1.
  • This mixture was then spray dried in a Niro Atomizer Portable Spray Dryer equipped with a two fluid atomizer (Niro Atomizer, Copenhagen, Denmark) employing the following settings: hot air flow rate 31 CFM inlet air temp. 325 °C outlet air temp. 120 °C atomizer air flow 290 liters/min emulsion feed rate 1.5 liter/hr
  • the dry, hollow spherical product had a diameter between about 1 ⁇ M and about 15 ⁇ M and was collected at the cyclone separator as is standard for this dryer.
  • Aliquots of powder 200 mg were weighed into 10 ml tubing vials, sparged with perfluorodiglyme-saturated nitrogen at 20°C and sealed. The nitrogen was saturated with perfluorodiglyme by passing it through three perfluorodiglyme filled gas washing bottles immersed in a 20°C water bath. The amount of perfluorodiglyme vapor per vial was 12-14 mg.
  • the vials were reconstituted with 5 ml water for injection after inserting an 18-gauge needle as a vent to relieve pressure as the water was injected, forming approximately 3 x 10 8 bubbles per ml which were stable in vitro for several days.
  • One ml of the resulting microbubble suspension was injected intravenously into an approximately 3 kg rabbit instrumented to monitor the Doppler ultrasound signal of its carotid artery.
  • a 10 MHz flow cuff (Triton Technology Inc., San Diego, CA; model ES-10-20) connected to a System 6 Doppler flow module (Triton Technology Inc.) fed the RF Doppler signal to a LeCroy 9410 oscilloscope (LeCroy, Chestnut Ridge, NY).
  • the root mean square (RMS) voltage of the signal computed by the oscilloscope was transferred to a computer and the resultant curve fitted to obtain peak echogenic signal intensity and half-life of the microbubbles in blood. Signals before contrast were less than 0.1 volts RMS.
  • signal intensity was 0.4 V rms, with a decay constant of approximately .01835 s -1
  • Solution 2 was added to high shear mixer and cooled in an ice bath.
  • a coarse suspension of 30 ml of 1,1 ,2-trichlorotrifluoroethane (Freon 113; EM Science, Gibbstown, NJ) was made in the 1 liter of solution 2.
  • This suspension was emulsified using a Microfluidizer (Microfluidics Corporation, Newton, MA; model M-110F) at 10,000 psi, 5°C for 5 passes.
  • the resulting emulsion was added to solution 1.
  • This mixture was then spray dried in a Niro Atomizer Portable Spray Dryer equipped with a two fluid atomizer (Niro Atomizer, Copenhagen, Denmark) employing the following settings: hot air flow rate 31 CFM inlet air temp. 325 °C outlet air temp. 120 °C atomizer air flow 290 liters/min emulsion feed rate 1.5 liter/hr
  • the dry, hollow spherical product had a diameter between about 1 ⁇ M and about 15 ⁇ M and was collected at the cyclone separator as is standard for this dryer.
  • Aliquots of powder 200 mg were weighed into 10 ml tubing vials, sparged with perfluorodiglyme-saturated nitrogen at 13°C and sealed. The nitrogen was saturated with perfluorodiglyme by passing it through three perfluorodiglyme filled gas washing bottles immersed in a 13°C water bath. The amount of perfluorodiglyme vapor per vial was 12-14 mg.
  • the vials were reconstituted with 5 ml water for injection after inserting an 18-gauge needle as a vent to relieve pressure as the water was injected, forming approximately 2 x 10 8 bubbles per ml which were stable in vitro for several days.
  • One ml of the resulting microbubble suspension was injected intravenously into an approximately 3 kg rabbit instrumented to monitor the Doppler ultrasound signal of its carotid artery.
  • a 10 MHz flow cuff (Triton Technology Inc., San Diego, CA; model ES-10-20) connected to a System 6 Doppler flow module (Triton Technology Inc.) fed the RF doppler signal to a LeCroy 9410 oscilloscope (LeCroy, Chestnut Ridge, NY).
  • the root mean square (RMS) voltage of the signal computed by the oscilloscope was transferred to a computer and the resultant curve fitted to obtain peak echogenic signal intensity and half-life of the microbubbles in blood. Signals before contrast were less than 0.1 volts RMS.
  • signal intensity was 0.2 V rms, with a decay constant of approximately .00387 s -1 .
  • the surfactants form mixed micelles only.
  • 5 ml water approximately 51 million gas emulsion droplets per ml were observed, ranging in size from 1 to 20 microns.
  • the gas emulsion was assayed for complement activation using an in-vitro C3a diagnostic kit supplied by Quidel Corp. (San Diego, CA). No difference between the gas emulsion and the negative control (saline) were observed, indicating that the gas emulsion does not activate complement. It is well known that naked microbubbles activate complement.
  • the gas emulsion was also assayed for changes in hemodynamics in anesthetized dogs at a dose of 20 mg/kg. No changes in mean arterial pressure or pulmonary artery pressure were observed. These results indicate that no hemodynamic effects are observed with the gas emulsion at 10-100 times the clinically relevant dose.
  • Time (minutes) Mean Arterial Pulmonary Artery Pressure (mmHg) Pressure (mmHg) 0 109.4 13.3 1 109.2 14.2 2 110.4 14.1 5 115.0 14.3 10 117.9 15.7 60 111.0 13.2 90 120.9 13.6
  • the needle sealing cover was removed to eliminate pressure buildup in the powder chamber.
  • the plunger was then depressed, forcing the interchamber seal to the bypass position which allowed the water to flow around the interchamber seal into the powder-containing chamber.
  • the plunger motion was stopped when all the water was in the powder chamber.
  • the syringe was agitated to dissolve the powder. Excess gas and any large bubbles were expelled by holding the syringe, needle end up, and further depressing the plunger.
  • the solution containing numerous stabilized microbubbles was then expelled from the syringe by depressing the plunger to its limit.
  • Example III One liter of the dispersion A was prepared and spray dried as described in Example III, and one liter of dispersions B and C were prepared and spray dried as described in Example V.
  • Powder Filling gas Amount of osmotic filling gas per vial, mg/atm Doppler signal, V, 100 s after injection Doppler signal, 300 s after injection 1 24f CF 3 OCF 3 16.5mg/0.26 atm 0.3 0.1 2 24f CF 3 OC 2 F 5 38 mg/ 0.46 atm 0.8 0.2 3 24f n-C 3 F 8 49.7mg/0.65 atm 0.6 0 4 24f air - 0 0 5 24b C 2 F 5 OC 2 F 5 48.2mg/0.46 atm 1.25 0.6 6 24b n-C 4 F 10 50 mg/0.51 atm 1.0 0.5 7 AF0145 CF 3 OC 2 F 5 41.7 mg/0.50 atm 0.75 0.1 8 AF0145 air - 0 0 0
  • the present invention provides a stable gas dispersion or emulsion that is suitable for use as ultrasound and magnetic resonance imaging (MRI) contrast enhancement agents wherein the bubbles have a prolonged longevity in vivo.
  • Typical ultrasound contrast enhancement agents only exhibit contrast enhancement potential for approximately one pass through the arterial system, or a few seconds to about a minute. Accordingly, such agents are not generally circulated past the aorta in a patient following intravenous injection.
  • stable contrast agents prepared in accordance with the present invention continue to demonstrate contrast enhancement duration sufficient for multiple passes through the entire circulatory system of a patient following intravenous injection. In vivo bubble lives of several minutes are easily demonstrated. Such lengthening of contrast enhancement potential during ultrasound is highly advantageous.
  • the contrast enhancement agents of the invention provide superior imaging. For example, clear, vivid, and distinct images of blood flowing through the heart, liver, and kidneys are achieved. Thus small, nontoxic doses of the compositions of the present invention can be administered in a peripheral vein and used to enhance images of the entire body.
  • Powder D was prepared as described in Example XI and filled with perfluorohexane-N 2 mixture (28mg of osmotic agent per vial, partial pressure 0.16 atm) and C 5 F 12 O 4 -N 2 mixture (22 mg of osmotic agent per vial, partial pressure 0.12 atm). After reconstituting the powder with 10 ml of water, the bubbles were formed.
  • Anesthetized pigs (14-16 kg) were fitted with indwelling catheters in the femoral artery and femoral and jugular veins for hemodynamic monitoring and contrast agent administration.
  • Parastemal short-axis cardiac images at the level of the papillary muscles were obtained using an HP Sonos 2500 Ultrasound machine. Images were acquired in the Second Harmonic mode with a wide bandwidth linear phased array probe emitting at 2 MHz and receiving at 4 MHz. Imaging was intermittent (gated), triggered at end-diastole of every cardiac cycle.
  • 0.5 mL of reconstituted contrast agent was diluted with 0.5mL sterile saline and infused over 1 min via the jugular vein.
  • Figures 3a, 3b and 3c represent an image of the heart before infusing the contrast agent (3a), one minute (3b) and six minutes (3c) after injection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acoustics & Sound (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
EP01119824A 1995-06-07 1996-06-05 Gasemulsionen, die durch fluorierte Ether mit niedriegen Ostwaldkoeffizienten, stabilisiert sind. Expired - Lifetime EP1174153B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US479621 1995-06-07
US08/479,621 US5804162A (en) 1995-06-07 1995-06-07 Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
EP96918164A EP0833669B1 (de) 1995-06-07 1996-06-05 Gasemulsionen, die durch fluorierte ether mit niedrigen ostwaldkoeffizienten stabilisiert sind

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP96918164A Division EP0833669B1 (de) 1995-06-07 1996-06-05 Gasemulsionen, die durch fluorierte ether mit niedrigen ostwaldkoeffizienten stabilisiert sind

Publications (3)

Publication Number Publication Date
EP1174153A2 true EP1174153A2 (de) 2002-01-23
EP1174153A3 EP1174153A3 (de) 2002-07-31
EP1174153B1 EP1174153B1 (de) 2006-08-23

Family

ID=23904745

Family Applications (2)

Application Number Title Priority Date Filing Date
EP96918164A Expired - Lifetime EP0833669B1 (de) 1995-06-07 1996-06-05 Gasemulsionen, die durch fluorierte ether mit niedrigen ostwaldkoeffizienten stabilisiert sind
EP01119824A Expired - Lifetime EP1174153B1 (de) 1995-06-07 1996-06-05 Gasemulsionen, die durch fluorierte Ether mit niedriegen Ostwaldkoeffizienten, stabilisiert sind.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP96918164A Expired - Lifetime EP0833669B1 (de) 1995-06-07 1996-06-05 Gasemulsionen, die durch fluorierte ether mit niedrigen ostwaldkoeffizienten stabilisiert sind

Country Status (18)

Country Link
US (2) US5804162A (de)
EP (2) EP0833669B1 (de)
JP (1) JP4067116B2 (de)
KR (1) KR100401429B1 (de)
CN (1) CN1087954C (de)
AT (2) ATE337018T1 (de)
AU (1) AU712946B2 (de)
CA (1) CA2222186A1 (de)
CZ (1) CZ391397A3 (de)
DE (2) DE69621015T2 (de)
DK (1) DK0833669T3 (de)
ES (2) ES2269262T3 (de)
HU (1) HUP9900848A3 (de)
IL (1) IL122217A (de)
NO (1) NO975317L (de)
PL (1) PL185883B1 (de)
PT (1) PT833669E (de)
WO (1) WO1996040281A2 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
JP3559849B2 (ja) * 1993-07-30 2004-09-02 アイエムシーオーアール ファーマシューティカル カンパニー 超音波技術のための安定化された微小気泡組成物
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
JP2001507207A (ja) 1996-05-01 2001-06-05 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 化合物を細胞に送達する方法
EP0915738B1 (de) * 1996-08-05 2002-01-16 Schering Aktiengesellschaft Vorrichtung und verfahren zur abtrennung magnetischer materialien aus pharmazeutischen zubereitungen, deren ausgangs- oder zwischenprodukten sowie mit hilfe dieser vorrichtung hergestellte mittel
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
ES2289188T3 (es) 1996-09-11 2008-02-01 Bristol-Myers Squibb Medical Imaging, Inc. Procedimiento para la obtencion de imagenes para el diagnostico usando un agente de contraste y un vasodilatador.
DE69721331T2 (de) * 1996-10-21 2004-05-06 Amersham Health As Verbesserungen für oder in bezug auf kontrastmitteln in ultraschallbilddarstellung
WO1998023298A1 (en) * 1996-11-25 1998-06-04 Imarx Pharmaceutical Corp. Perfluorinated-ether compositions as diagnostic contrast agents
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6548047B1 (en) * 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
JP2002506625A (ja) 1998-03-19 2002-03-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド サイトカインレセプター共通γ鎖様
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US20040010134A1 (en) 2000-04-12 2004-01-15 Rosen Craig A. Albumin fusion proteins
US6270460B1 (en) * 1999-06-24 2001-08-07 Acuson Corporation Apparatus and method to limit the life span of a diagnostic medical ultrasound probe
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP2431054A3 (de) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Menschlicher Tumornekrosefaktor Delta und Ypsilon
US6849194B2 (en) 2000-11-17 2005-02-01 Pcbu Services, Inc. Methods for preparing ethers, ether compositions, fluoroether fire extinguishing systems, mixtures and methods
EP1683865A3 (de) 2001-02-02 2006-10-25 Eli Lilly & Company Säugerproteine und insbesondere CD200
CN1564826A (zh) 2001-02-09 2005-01-12 人类基因组科学公司 人类g蛋白趋化因子受体(ccr5)hdgnr10
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
DE10119522A1 (de) * 2001-04-20 2002-12-05 Innovacell Biotechnologie Gmbh Herstellung und Anwendung einer Suspensionszusammensetzung mit einem Ultraschall-Kontrastmittel
DK1463751T3 (da) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albuminfusionsproteiner.
CA2472282A1 (en) 2002-01-08 2003-07-17 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
US7300743B2 (en) * 2003-03-06 2007-11-27 E. I. Du Pont De Nemours And Company Radiation durable organic compounds with high transparency in the vacuum ultraviolet, and method for preparing
EP1628992A4 (de) 2003-05-13 2008-04-16 Novartis Vaccines & Diagnostic Verfahren zur modulation der metastasierung sowie von metastasen herrührender verwandter ereignisse im skelett
US20050074406A1 (en) * 2003-10-03 2005-04-07 Scimed Life Systems, Inc. Ultrasound coating for enhancing visualization of medical device in ultrasound images
EP1729795B1 (de) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albuminfusionsproteine
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
JP5189977B2 (ja) 2005-07-19 2013-04-24 ステムジェン ソシエタ ペル アチオニ Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制
US7943134B2 (en) 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
CA2628238A1 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2009118300A1 (en) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
EP2280736B1 (de) * 2008-05-02 2016-11-02 Celsense Inc. Zusammensetzungen und verfahren zur herstellung von emulsionen für kernmagnetresonanzverfahren und andere anwendungen
GB0811856D0 (en) 2008-06-27 2008-07-30 Ucl Business Plc Magnetic microbubbles, methods of preparing them and their uses
US20100160576A1 (en) * 2008-11-21 2010-06-24 University Of Tennessee Research Foundation Perfluorinated poly(oxymethylene) compounds
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
US20120244170A1 (en) 2009-09-22 2012-09-27 Rafal Ciosk Treating cancer by modulating mex-3
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
US20130004519A1 (en) 2010-03-05 2013-01-03 Ruth Chiquet-Ehrismann Smoci, tenascin-c and brain cancers
US20130034543A1 (en) 2010-04-19 2013-02-07 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Modulating xrn1
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
EP2717911A1 (de) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Proteintyrosinphosphatase, nicht-rezeptor typ 11 (ptpn11) und dreifach negativer brustkrebs
EP2776838A1 (de) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Frühe diagnose neurodegenerativer erkrankungen
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20140363448A1 (en) 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
JP2013180956A (ja) * 2012-02-29 2013-09-12 Sunstar Engineering Inc 殺菌剤組成物
EP2831112A1 (de) 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Hemmung von interleukin 8 und/oder dessen rezeptor cxcrl bei der behandlung von brustkrebs mit her2/her3-überexpression
EP2866831A1 (de) 2012-06-29 2015-05-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krankheiten durch modulation einer spezifischen isoform von mkl1
EP2870242A1 (de) 2012-07-05 2015-05-13 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Neue behandlung für neurodegenerative erkrankungen
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
ES2761587T3 (es) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
EP3154579A1 (de) 2014-06-13 2017-04-19 Friedrich Miescher Institute for Biomedical Research Neue behandlung gegen das influenzavirus
EP3157535A1 (de) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Verfahren zur auslösung der novo-bildung von heterochromatin und/oder zur epigenetischen abschaltung mit kleinen rnas
WO2016001830A1 (en) 2014-07-01 2016-01-07 Friedrich Miescher Institute For Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
EP3197557A1 (de) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats und brustrkrebs
CN104353088A (zh) * 2014-09-30 2015-02-18 东南大学 一种脂质气泡的制备方法
US10052394B2 (en) 2014-11-21 2018-08-21 General Electric Company Microbubble tether for diagnostic and therapeutic applications
NZ733010A (en) 2014-12-31 2023-01-27 Lantheus Medical Imaging Inc Lipid-encapsulated gas microsphere compositions and related methods
WO2017072669A1 (en) 2015-10-28 2017-05-04 Friedrich Miescher Institute For Biomedical Research Tenascin-w and biliary tract cancers
EP3176206A1 (de) * 2015-12-01 2017-06-07 Evonik Degussa GmbH Verfahren zur herstellung feinzelliger schaumstoffe unter verwendung eines zellalterungshemmers
IL262647B2 (en) 2016-05-04 2023-03-01 Lantheus Medical Imaging Inc Methods and devices for preparing sharpness factors for ultrasound
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11225689B2 (en) 2016-08-17 2022-01-18 The Broad Institute, Inc. Method for determination and identification of cell signatures and cell markers
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3606518A4 (de) 2017-04-01 2021-04-07 The Broad Institute, Inc. Verfahren und zusammensetzungen zur detektion und zur modulation einer immuntherapieresistenzgensignatur in krebs
WO2019079362A1 (en) 2017-10-16 2019-04-25 Massachusetts Institute Of Technology HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US20210386829A1 (en) 2018-05-04 2021-12-16 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2020077236A1 (en) 2018-10-12 2020-04-16 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020172343A2 (en) 2019-02-19 2020-08-27 Massachusetts Institute Of Technology Methods for treating injuries
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020186235A1 (en) 2019-03-14 2020-09-17 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
EP3942023A1 (de) 2019-03-18 2022-01-26 The Broad Institute, Inc. Zusammensetzungen und verfahren zur modulation metabolischer regulatoren der t-zell-pathogenität
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
US20220243178A1 (en) 2019-05-31 2022-08-04 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
WO2024016003A2 (en) 2022-07-14 2024-01-18 The Broad Institute, Inc. Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052575A2 (de) * 1980-11-17 1982-05-26 Schering Aktiengesellschaft Präparat zur Erzeugung von Mikrobläschen
US4684479A (en) * 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
WO1996026746A1 (en) * 1995-02-28 1996-09-06 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
WO1999053964A1 (en) * 1998-04-22 1999-10-28 Nycomed Imaging As Ultrasound contrast agent dispersions comprising gas and destabilising agent
WO1999053963A1 (en) * 1998-04-22 1999-10-28 Marsden, John, Christopher Improvements in or relating to contrast agents

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276885A (en) * 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
US4657756A (en) * 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
DE3141641A1 (de) * 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Ultraschall-kontrastmittel und dessen herstellung
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
DE3313947A1 (de) * 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
US5141738A (en) * 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
DE3324754A1 (de) * 1983-07-06 1985-01-17 Schering AG, 1000 Berlin und 4709 Bergkamen Ultraschallkontrastmittel sowie dessen herstellung
GB8504916D0 (en) * 1985-02-26 1985-03-27 Isc Chemicals Ltd Emulsions of perfluorocarbons in aqueous media
US5186922A (en) * 1985-03-15 1993-02-16 See/Shell Biotechnology, Inc. Use of biodegradable microspheres labeled with imaging energy constrast materials
US4613326A (en) * 1985-07-12 1986-09-23 Becton, Dickinson And Company Two-component medication syringe assembly
DE3529195A1 (de) * 1985-08-14 1987-02-26 Max Planck Gesellschaft Kontrastmittel fuer ultraschalluntersuchungen und verfahren zu seiner herstellung
EP0247156B1 (de) * 1985-11-18 1993-06-23 Access Pharmaceuticals Inc. Polychelierende stoffe für abbildung- und spektralerhöhung (und spektrale verschiebung)
US4927623A (en) * 1986-01-14 1990-05-22 Alliance Pharmaceutical Corp. Dissolution of gas in a fluorocarbon liquid
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
EP0231091B1 (de) * 1986-01-24 1993-03-31 Children's Hospital Medical Center Stabile Emulsionen von stark fluorierten, organischen Verbindungen
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US4781676A (en) * 1987-02-20 1988-11-01 Air Products And Chemicals, Inc. Interstitial administration of perfluorochemical emulsions for reoxygenation of hypoxic tumor cells
US5108759A (en) * 1987-04-01 1992-04-28 Ranney David F Endothelial envelopment drug carriers
DE3741201A1 (de) * 1987-12-02 1989-06-15 Schering Ag Ultraschallarbeitsverfahren und mittel zu dessen durchfuehrung
DE3741199A1 (de) * 1987-12-02 1989-08-17 Schering Ag Verwendung von ultraschallkontrastmitteln fuer die ultraschall-lithotripsie
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
DE58908194D1 (de) * 1988-02-05 1994-09-22 Schering Ag Ultraschallkontrastmittel, verfahren zu deren herstellung und deren verwendung als diagnostika und therapeutika.
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
US5171755A (en) * 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
US4957656A (en) * 1988-09-14 1990-09-18 Molecular Biosystems, Inc. Continuous sonication method for preparing protein encapsulated microbubbles
US5149319A (en) * 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5123414A (en) * 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5228446A (en) * 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5209720A (en) * 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
DE4004430A1 (de) * 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
GB9003821D0 (en) * 1990-02-20 1990-04-18 Danbiosyst Uk Diagnostic aid
US5445813A (en) * 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
IN172208B (de) * 1990-04-02 1993-05-01 Sint Sa
US5556610A (en) * 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
GB9009423D0 (en) * 1990-04-26 1990-06-20 Williams Alun R Assessment of vascular perfusion by the display of harmonic echoes from ultrasonically excited gas bubbles
US5205287A (en) * 1990-04-26 1993-04-27 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) * 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5315997A (en) * 1990-06-19 1994-05-31 Molecular Biosystems, Inc. Method of magnetic resonance imaging using diamagnetic contrast
JP2599492B2 (ja) * 1990-08-21 1997-04-09 第一製薬株式会社 リポソーム製剤の製造法
WO1992005806A1 (en) * 1990-10-05 1992-04-16 Sintetica S.A. Method for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography
DE4100470A1 (de) * 1991-01-09 1992-07-16 Byk Gulden Lomberg Chem Fab Echokontrastmittel
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
CA2063529A1 (en) * 1991-03-22 1992-09-23 Katsuro Tachibana Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
WO1992021382A1 (en) * 1991-06-03 1992-12-10 Holmes, Michael, John Improvements in or relating to contrast agents
DK0593624T3 (da) * 1991-07-05 1997-05-20 Nycomed Imaging As Forbedringer af eller i relation til kontrastmidler
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
WO1993003671A1 (en) * 1991-08-13 1993-03-04 Molecular Biosystem, Inc. Method of mri imaging using diamagnetic contrast agents
WO1993005819A1 (en) * 1991-09-17 1993-04-01 Sonus Pharmaceuticals, Inc Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media
MX9205298A (es) * 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
WO1993006869A1 (en) * 1991-10-04 1993-04-15 Mallinckrodt Medical, Inc. Gaseous ultrasound contrast agents
US5304325A (en) * 1991-11-13 1994-04-19 Hemagen/Pfc Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use
US5196183A (en) * 1991-12-04 1993-03-23 Sterling Winthrop Inc. Contrast agents for ultrasound imaging
GB9200388D0 (en) * 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) * 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
DE4219723A1 (de) * 1992-06-13 1993-12-16 Schering Ag Mikropartikel, Verfahren zu deren Herstellung, sowie die Verwendung dieser in der Diagnostik
AU4563093A (en) * 1992-07-03 1994-01-31 Byk Gulden Lomberg Chemische Fabrik Gmbh Echographic contrast agent composition
AU689086B2 (en) * 1992-09-16 1998-03-26 Nycomed Imaging As Improvements in or relating to contrast agents
US5314644A (en) * 1992-10-19 1994-05-24 Virginia Polytechnic Institute And State University Microbubble generator
WO1994009703A1 (en) * 1992-11-02 1994-05-11 Drexel University Surfactant-stabilized microbubble mixtures, process for preparing and methods of using the same
US5393527A (en) * 1993-01-04 1995-02-28 Becton, Dickinson And Company Stabilized microspheres and methods of preparation
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
ATE200985T1 (de) * 1993-01-25 2001-05-15 Sonus Pharma Inc Phase-stift kolloide zur verwendung als ultraschallkontrastmittel
ATE264671T1 (de) * 1993-02-22 2004-05-15 American Bioscience Inc Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
GB9305349D0 (en) * 1993-03-16 1993-05-05 Nycomed Imaging As Improvements in or relating to contrast agents
US5333613A (en) * 1993-03-23 1994-08-02 Delineate Microparticles as ultrasonic contrast media
US5716597A (en) * 1993-06-04 1998-02-10 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
CN1068229C (zh) * 1993-12-15 2001-07-11 勃勒柯研究有限公司 超声对比介质、含该介质的对比剂及方法
DE4406474A1 (de) * 1994-02-23 1995-08-24 Schering Ag Gas enthaltende Mikropartikel, diese enthaltende Mittel, deren Verwendung in der Ultraschalldiagnostik, sowie Verfahren zur Herstellung der Partikel und Mittel
US5502094A (en) * 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5562893A (en) * 1994-08-02 1996-10-08 Molecular Biosystems, Inc. Gas-filled microspheres with fluorine-containing shells
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052575A2 (de) * 1980-11-17 1982-05-26 Schering Aktiengesellschaft Präparat zur Erzeugung von Mikrobläschen
US4684479A (en) * 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
WO1996026746A1 (en) * 1995-02-28 1996-09-06 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
WO1999053964A1 (en) * 1998-04-22 1999-10-28 Nycomed Imaging As Ultrasound contrast agent dispersions comprising gas and destabilising agent
WO1999053963A1 (en) * 1998-04-22 1999-10-28 Marsden, John, Christopher Improvements in or relating to contrast agents

Also Published As

Publication number Publication date
WO1996040281A2 (en) 1996-12-19
MX9709564A (es) 1998-10-31
AU712946B2 (en) 1999-11-18
HUP9900848A2 (hu) 1999-07-28
PT833669E (pt) 2002-09-30
DE69636486D1 (de) 2006-10-05
ATE337018T1 (de) 2006-09-15
US6193952B1 (en) 2001-02-27
PL323868A1 (en) 1998-04-27
CN1192159A (zh) 1998-09-02
EP1174153B1 (de) 2006-08-23
IL122217A0 (en) 1998-04-05
NO975317D0 (no) 1997-11-19
WO1996040281B1 (en) 2001-04-05
WO1996040281A3 (en) 1997-03-13
EP1174153A3 (de) 2002-07-31
CN1087954C (zh) 2002-07-24
KR19990022594A (ko) 1999-03-25
PL185883B1 (pl) 2003-08-29
KR100401429B1 (ko) 2004-02-18
DE69621015T2 (de) 2002-12-19
CZ391397A3 (cs) 1998-05-13
IL122217A (en) 2002-03-10
ES2176462T3 (es) 2002-12-01
JP4067116B2 (ja) 2008-03-26
CA2222186A1 (en) 1996-12-19
DE69621015D1 (de) 2002-06-06
ATE216894T1 (de) 2002-05-15
DE69636486T2 (de) 2007-05-03
JPH11506782A (ja) 1999-06-15
NO975317L (no) 1998-01-09
AU6048796A (en) 1996-12-30
HUP9900848A3 (en) 1999-11-29
EP0833669A2 (de) 1998-04-08
DK0833669T3 (da) 2002-08-12
EP0833669B1 (de) 2002-05-02
ES2269262T3 (es) 2007-04-01
US5804162A (en) 1998-09-08

Similar Documents

Publication Publication Date Title
EP0833669B1 (de) Gasemulsionen, die durch fluorierte ether mit niedrigen ostwaldkoeffizienten stabilisiert sind
WO1996040281A9 (en) Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients
JP3559849B2 (ja) 超音波技術のための安定化された微小気泡組成物
KR100407755B1 (ko) 초음파조영용의,인지질을함유한안정화된기체에멀젼
US20030138380A1 (en) Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
AU731099B2 (en) Stablized microbubble compositions for ultrasound
AU1759000A (en) Gas emulsions stabilized with flourinated ethers having low Ostwald coefficients
MXPA97009564A (es) Emulsiones de gas estabilizadas con eteres fluorados que tienen coeficientes bajos de ostwald
AU5775101A (en) Stabilized microbubble compositions for ultrasound
MXPA97006402A (es) Emulsión de gas estabilizada, que contiene fosfolipidos para aumentar el contraste del ultrasonido

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 833669

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WEERS, JEFFREY GREG

Inventor name: SCHUTT, ERNEST GEORGE

Inventor name: KABALNOV, ALEXEY

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 49/00 A, 7A 61K 49/22 B, 7A 61K 49/18 B

17P Request for examination filed

Effective date: 20030128

17Q First examination report despatched

Effective date: 20030304

AKX Designation fees paid

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMCOR PHARMACEUTICAL CO.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 0833669

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20060823

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060823

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060823

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060823

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060823

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060823

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060823

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69636486

Country of ref document: DE

Date of ref document: 20061005

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061123

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070124

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2269262

Country of ref document: ES

Kind code of ref document: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20070626

Year of fee payment: 12

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20070731

Year of fee payment: 12

26N No opposition filed

Effective date: 20070524

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20070628

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20070626

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061124

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20070618

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070605

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20080605

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20090228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080605

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20080606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070605

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080605

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080606